Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards

This article was originally published in The Pink Sheet Daily

Executive Summary

Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.

You may also be interested in...



Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities

MUMBAI - An extensive worldwide search for novel agents to treat chronic neuropathic pain has brought together Sanofi-Aventis and Indian drug maker Glenmark Pharma through a development and commercialization deal for transient receptor potential vanilloid (TRPV3) antagonist molecules

Glenmark's Lead Compound For COPD Fails; Forest To Wait For 2010 Studies In Asthma Patients

MUMBAI - Hopes of a novel drug to treat smoking-induced lung disease were dashed after India's Glenmark Pharma and its U.S.-based research partner Forest Labs announced that the compound under development in Phase IIb human trials failed to meet efficacy endpoints

Lilly Halts Development of Glenmark’s TRVP-1 Receptor Antagonist

MUMBAI - Glenmark Pharmaceuticals suffered a major blow to its drug discovery plans as Eli Lilly, its research partner for the development of pain management compound GRC 6211 suspended further clinical development on the experimental drug

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070966

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel